Table 1 Alzheimer’s disease-related mechanisms of action of repurposed agents in the pipeline (ClinicalTrials.gov as of February 27, 2020)
From: Repurposed agents in the Alzheimer’s disease drug development pipeline
Approved therapeutic area | Disease-modifying therapies | Cognitive enhancers | Behavioral symptoms | Behavioral + cognitive symptoms | Total # of agents (%) |
|---|---|---|---|---|---|
Hematologic-oncologic | 10 | – | – | – | 10 (20.0) |
Cardiovascular | 7 | 1 | 1 | – | 9 (18.0) |
Psychiatric | 1 | 1 | 4 | 1 | 7 (14.0) |
Antidiabetic | 6 | – | – | – | 6 (12.0) |
Neurologic | 3 | – | 2 | – | 5 (10.0) |
Infectious disease | 3 | – | – | – | 3 (6.0) |
Anti-inflammatory | 2 | – | – | – | 2 (4.0) |
Genetics | 1 | – | – | – | 1 (2.0) |
Cannabinoid | – | – | 1 | – | 1 (2.0) |
Hormonal | 1 | – | – | – | 1 (2.0) |
Immunologic | 1 | – | – | – | 1 (2.0) |
Alkaloid | – | 1 | – | – | 1 (2.0) |
Pulmonary | 1 | – | – | – | 1 (2.0) |
Nutraceutical | 1 | – | – | – | 1 (2.0) |
Vitamin | 1 | – | – | – | 1 (2.0) |
TOTAL | 38 | 3 | 8 | 1 | 50 (100.0) |